Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Curr Opin Virol. 2012 Jul 6;2(4):508–514. doi: 10.1016/j.coviro.2012.06.004

Table 1.

Examples of estimated usage of SV40-contaminated oral poliovaccinesa,b

Country Source of OPVc Date of usage Estimated no. of vaccinees
Belgian Congo CHAT 1958 240,000
Colombia Lederle 1958–1959 140,000
Costa Rica Lederle 1959–1960 272,000
Croatia CHAT 1960 1.3 million
Czechoslovakia Sabin 1958–1959 143,000
Egyptd Russian NAd NA
Hungary Russian 1960–1978 (est.) 2.5 million (1960)
Japan Russian 1961–1963 ~15 million
Mexico Sabin 1958–1959 308,000
Nicaragua Lederle 1958–1959 42,000
Poland CHAT 1959 9 million
Uruguay Lederle 1958–1959 218,000
USA, Cincinnati Sabin 1960 181,000
USA, Miami Lederle 1959 410,000
USSR Russian 1959–1978 (est.) Many millions
a

See Butel [23,34] for original references. The list is not comprehensive.

b

Mainly children were vaccinated.

c

OPV, oral poliovaccine; CHAT, Koprowski candidate vaccine that was based on the same poliovirus strains as Lederle Laboratories’ candidate vaccine; Russian OPV was based on Sabin vaccine virus strains.

d

NA, not available. Parenteral antischistosomal therapy was provided in Egypt until the 1980s.